Early and Long-Term Efficacy and Immune Changes With Dupilumab in Prurigo Nodularis

UMC Utrecht

Status: Enrolling

Conditions: Prurigo Nodularis (PN)

Treatments: Drug: Dupilumab

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT07276425

2023ESR0000155 (Other Identifier)

12-407

Details and patient eligibility

About

With the arrival of dupilumab as the first available targeted therapy for PN, there is an unmet need for real-world data and translational research on the working mechanism of dupilumab on PN, to optimize individualized targeted treatment.

Enrollment: 40 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients with moderate-to-severe prurigo nodularis starting dupilumab treatment

Exclusion criteria

• Unwilling to participate in the BioDay registry
• (For translational endpoints only) Unwilling to participate in UMC Utrecht Biobank